SGS and Berlin Healthtech Startup theblood Form Strategic Partnership to Validate Menstrual Blood Diagnostics for Women’s Health

SGS and Berlin Healthtech Startup theblood Form Strategic Partnership to Validate Menstrual Blood Diagnostics for Women’s Health

(IN BRIEF) SGS has partnered with Berlin-based healthtech startup theblood to support the development and validation of diagnostic tools based on menstrual blood. Acting as an independent quality and validation partner, SGS will apply its pharmaceutical and bioanalytical expertise to ensure that menstrual blood is rigorously evaluated as a diagnostic matrix under high scientific and regulatory standards. The initiative aims to unlock new non-invasive diagnostic possibilities for female-specific conditions such as endometriosis, polycystic ovary syndrome and other fertility-related disorders. By embedding validation and quality processes early in development, the collaboration seeks to build trust among regulators, clinicians and patients and contribute to more inclusive and evidence-based healthcare solutions for women.

(PRESS RELEASE) BAAR, 12-Feb-2026 — /EuropaWire/ — SGS, the world’s leading testing, inspection and certification provider, has entered into a new partnership with theblood to support the scientific development and validation of women’s health diagnostics based on menstrual blood. The collaboration seeks to establish a rigorous scientific and regulatory framework that could enable a new non-invasive pathway for female-specific diagnostic testing.

Under the agreement, SGS will act as an independent quality and validation partner, bringing its global pharmaceutical and bioanalytical expertise to theblood’s research efforts. The focus will be on ensuring that menstrual blood, as a diagnostic matrix, is assessed and developed according to high standards of scientific integrity, quality control and regulatory compliance from the earliest stages of innovation.

Menstrual blood is increasingly viewed as a potentially valuable source of health data specific to women. It contains biomarkers that may support improved monitoring of inflammatory-related conditions such as endometriosis and polycystic ovary syndrome, as well as other fertility-related disorders. Despite this promise, menstrual blood remains a relatively underexplored biological matrix in clinical diagnostics, requiring robust validation to achieve broader medical acceptance.

Through the partnership, SGS will provide bioanalytical testing expertise and guidance on regulatory pathways, supporting theblood in generating reproducible and reliable data. Establishing controlled, quality-assured processes is considered essential for gaining the confidence of regulators, clinicians and patients. By embedding validation protocols early in product development, the collaboration aims to strengthen long-term trust in innovative diagnostic approaches.

Theblood is focused on systematically investigating menstrual blood as a clinically relevant, non-invasive source of health information. Its mission is to address long-standing data gaps in women’s health and expand diagnostic perspectives that may allow earlier detection and improved medical understanding of female-specific conditions.

The partnership reflects a shared objective of advancing evidence-based solutions in women’s healthcare and promoting inclusive innovation. By combining health technology entrepreneurship with established pharmaceutical testing and quality assurance capabilities, the two organisations aim to accelerate the responsible development of next-generation diagnostics.

SOURCE: SGS